New drug combo tested for ovarian cancer: will it work?
NCT ID NCT07402915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing how the antifungal drug itraconazole affects the levels of a new cancer drug, AZD5335, in the body. The study involves 24 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to understand drug interactions, not to treat the cancer directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5335 (antibody drug conjugate) and itraconazole
What this could lead to
If successful, this could help determine the right dose of AZD5335 when given with other drugs, potentially improving treatment for ovarian cancer.
What could go wrong
This is a very early Phase 1 study with only 24 people. It focuses on drug levels, not on curing cancer, and may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGBatumi, 6010, Georgia
-
Research Site
NOT_YET_RECRUITINGTbilisi, 0114, Georgia
-
Research Site
NOT_YET_RECRUITINGTbilisi, 112, Georgia
-
Research Site
RECRUITINGDublin, D07 R2WY, Ireland
-
Research Site
RECRUITINGLisbon, 1250-068, Portugal
-
Research Site
RECRUITINGBarcelona, 08023, Spain
-
Research Site
RECRUITINGLogroño, 26006, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
-
Research Site
RECRUITINGMadrid, 28050, Spain